Find News

Filter articles

Applied Filters

Showing 41 to 50 of 129 results

AstraZeneca forms health tech partnerships in China


AstraZeneca has announced partnerships with Chinese companies Alibaba and Tencent, in agreements that will use emerging technologies to improve healthcare in China.

Abe & Partners makes two promotions


Japan-based Abe & Partners has promoted Michiko Kinoshita as partner and Tomohiro Kazama as counsel.

Tilleke & Gibbins promotes IP enforcement specialist


Southeast Asia-based law firm Tilleke & Gibbins has appointed an IP enforcement specialist to partner.

Aslan acquires global rights to cancer treatment


Singapore-based Aslan Pharmaceuticals has acquired the full global rights to develop, manufacture and commercialise a cancer treatment.

Pfizer and Basilea extend Cresemba licence agreement to Asia-Pacific


Basilea Pharmaceutica and Pfizer have reached a deal for a licence agreement for the antifungal medication Cresemba to cover China and 16 countries in the Asia-Pacific region.

Sanofi leads the way for gene therapy patents: report


CPA Global has found that Sanofi files the most patents covering human gene therapy and also spends the most on them overall.

AIPPI 2017: Eli Lilly counsel discusses ‘convoluted’ Amgen v Sanofi ruling


A patent counsel at Eli Lilly discussed a recent dispute pitting Amgen against Sanofi and Regeneron, saying an appeals court ruling was convoluted.

WIPO and pharma industry join forces to promote patent access


The World Intellectual Property Organization (WIPO) has partnered with trade group the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) to boost access to patent information.

Australian government rejects recommendations on patent extension reform


The Australian government has rejected proposals by the Productivity Commission regarding extending the length of pharmaceutical patents.

Samsung makes move into novel drugs market

Japan, South Korea22-08-2017

Samsung’s biopharmaceutical arm Samsung Bioepis has agreed a deal with Takeda to tackle “unmet disease areas”, marking the South Korean company’s move into the novel drugs market.

Showing 41 to 50 of 129 results